Cargando…

Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing

Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy affecting many different body tissues, predominantly skeletal and cardiac muscles and the central nervous system. The expansion of CTG repeats in the DM1 protein-kinase (DMPK) gene is the genetic cause of the disease. The pathogen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izzo, Mariapaola, Battistini, Jonathan, Provenzano, Claudia, Martelli, Fabio, Cardinali, Beatrice, Falcone, Germana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101876/ https://www.ncbi.nlm.nih.gov/pubmed/35563013 http://dx.doi.org/10.3390/ijms23094622

Ejemplares similares

CRISPR/Cas9-Mediated Deletion of CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients
por: Provenzano, Claudia, et al.
Publicado: (2017)

High-throughput analysis of the RNA-induced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2
por: Cappella, Marisa, et al.
Publicado: (2018)

Noncoding RNAs: Emerging Players in Muscular Dystrophies
por: Falcone, Germana, et al.
Publicado: (2014)

Dysregulation of Circular RNAs in Myotonic Dystrophy Type 1
por: Voellenkle, Christine, et al.
Publicado: (2019)

Time-controlled and muscle-specific CRISPR/Cas9-mediated deletion of CTG-repeat expansion in the DMPK gene
por: Cardinali, Beatrice, et al.
Publicado: (2021)

Deregulated MicroRNAs in Myotonic Dystrophy Type 2
por: Greco, Simona, et al.
Publicado: (2012)

Circular RNAs in Muscle Function and Disease
por: Greco, Simona, et al.
Publicado: (2018)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

Disrupting the Molecular Pathway in Myotonic Dystrophy
por: Xing, Xiaomeng, et al.
Publicado: (2021)

Myotonic Dystrophy: From Molecular Pathogenesis to Therapeutics
por: Timchenko, Lubov
Publicado: (2022)

Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9
por: Wang, Yanlin, et al.
Publicado: (2018)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

Molecular Genetics and Genetic Testing in Myotonic Dystrophy Type 1
por: Savić Pavićević, Dušanka, et al.
Publicado: (2013)

Marathoning with myotonic dystrophy type 2 (proximal myotonic myopathy) and leukopenia
por: Finsterer, Josef, et al.
Publicado: (2017)

Endometriosis as Initial Manifestation of Myotonic Dystrophy Type-2
por: Finsterer, Josef, et al.
Publicado: (2021)

Dynamics and variability of transcriptomic dysregulation in congenital myotonic dystrophy during pediatric development
por: Hale, Melissa A, et al.
Publicado: (2022)

Excessive rest time during active phase is reliably detected in a mouse model of myotonic dystrophy type 1 using home cage monitoring
por: Golini, Elisabetta, et al.
Publicado: (2023)

Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1
por: Wojciechowska, Marzena, et al.
Publicado: (2014)

Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1
por: López-Morató, Marta, et al.
Publicado: (2018)

Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies
por: MEOLA, GIOVANNI
Publicado: (2013)

A Molecular Signature of Myalgia in Myotonic Dystrophy 2
por: Moshourab, Rabih, et al.
Publicado: (2016)

Desflurane anaesthesia in myotonic dystrophy
por: Gandhi, Ranju, et al.
Publicado: (2011)

Myotonic Dystrophy: An Anaesthetic Dilemma
por: Gupta, N, et al.
Publicado: (2009)

Cardiac involvement in myotonic dystrophy
por: Khalighi, Koroush, et al.
Publicado: (2015)

Steakhouse Syndrome in Myotonic Dystrophy
por: Ogasawara, Nobuhiko, et al.
Publicado: (2017)

Cutaneous findings in myotonic dystrophy
por: Kong, Ha Eun, et al.
Publicado: (2022)

Molecular characterization of myotonic dystrophy fibroblast cell lines for use in small molecule screening
por: Jenquin, Jana R., et al.
Publicado: (2022)

Molecular and Clinical Implications of Variant Repeats in Myotonic Dystrophy Type 1
por: Peric, Stojan, et al.
Publicado: (2021)

Mitigating RNA Toxicity in Myotonic Dystrophy using Small Molecules
por: Reddy, Kaalak, et al.
Publicado: (2019)

Genome Wide Identification of Aberrant Alternative Splicing Events in Myotonic Dystrophy Type 2
por: Perfetti, Alessandra, et al.
Publicado: (2014)

Microrna-221 and Microrna-222 Modulate Differentiation and Maturation of Skeletal Muscle Cells
por: Cardinali, Beatrice, et al.
Publicado: (2009)

Disease burden of myotonic dystrophy type 1
por: Landfeldt, Erik, et al.
Publicado: (2019)

Myotonic dystrophy type 2: the 2020 update
por: Meola, Giovanni
Publicado: (2020)

Cardiac Pathology in Myotonic Dystrophy Type 1
por: Mahadevan, Mani S., et al.
Publicado: (2021)

Targeting Myotonic Dystrophy Type 1 with Metformin
por: García-Puga, Mikel, et al.
Publicado: (2022)

TNNT2 Missplicing in Skeletal Muscle as a Cardiac Biomarker in Myotonic Dystrophy Type 1 but Not in Myotonic Dystrophy Type 2
por: Bosè, Francesca, et al.
Publicado: (2019)

Fuchs' Endothelial Corneal Dystrophy in Patients With Myotonic Dystrophy, Type 1
por: Winkler, Nelson S., et al.
Publicado: (2018)

Validation of plasma microRNAs as biomarkers for myotonic dystrophy type 1
por: Perfetti, A., et al.
Publicado: (2016)

Myotonic dystrophy type 1 drug development: A pipeline toward the market
por: Pascual-Gilabert, Marta, et al.
Publicado: (2021)

Clinical and Molecular Insights into Gastrointestinal Dysfunction in Myotonic Dystrophy Types 1 & 2
por: Peterson, Janel A. M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_liq4ojecdhfnaih3gkmelqki56